Upgrade to SI Premium - Free Trial

Biogen (BIIB) CFO Transition Raises Questions Considering Pipeline - Mizuho Securities

July 22, 2020 7:10 AM
Mizuho Securities analyst Salim Syed reiterated a Neutral rating and $316.00 price target on Biogen (NASDAQ: BIIB) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles